Yue, Z.X., Huang, C., Gao, C., Xing, T.Y., Liu, S.G., Li, X.J., et al. (2017) MYCN Amplification Predicts Poor Prognosis Based on Interphase Fluorescence in Situ Hybridization Analysis of Bone Marrow Cells in Bone Marrow Metastases of Neuroblastoma. Cancer Cell International, 17.

has been cited by the following article:

• TITLE: N-Myc Inhibition: Advances in Neuroblastoma Treatment

  AUTHORS: Md Kamrul Hasan

  KEYWORDS: Neuroblastoma, N-Myc, PI3K/mTOR, PARP1, PD-L1, HAUSP

  JOURNAL NAME: CellBio, Vol.6 No.3, September 30, 2017

  ABSTRACT: Neuroblastoma (NBL) is one of the most common solid tumors and around 15% of cancer mortality in children. Amplification of the N-Myc proto-oncogene is strongly correlated with advanced disease and poor clinical outcome in NBL. Recent studies described that ubiquitin-specific protease 7 (USP7; also known as HAUSP) interacts with N-Myc, induces deubiquitination and subsequent stabilization of N-Myc that in-turn potentiates N-Myc function, and treatment with the HAUSP inhibitor (P22077) blocked such effects.